Deutsche Bank lowers Merck KGaA price target to EUR133 on mixed Q2\n\nInvesting.com - Deutsche Bank lowered its price target on Merck KGaA (ETR:MRK) (OTC:MKGAF) to EUR133.00 from EUR140.00 while maintaining a Buy rating following the company’s mixed second-quarter results.\n\nThe research firm cited the need for a quarter that triggers positive consensus earnings revisions to help the stock regain momentum after recent downward adjustments to estimates.\n\nDeutsche Bank expressed optimism that Merck’s 2025 guidance has been reduced enough to potentially achieve stabilization with upcoming third-quarter results.\n\nDespite growing investor frustration with Merck’s group structure, Deutsche Bank believes there remains underlying value to be unlocked with the current corporate setup.\n\nThe new price target of EUR133 represents more than 20% upside potential from current levels, with Deutsche Bank remaining positive on the investment case due to attractive valuation and improving performance in Merck’s Life Science business.\n\nThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Deutsche Bank lowers Merck KGaA price target to EUR133 on mixed Q2

Deutsche Bank has reduced its price target for Merck KGaA from EUR140.00 to EUR133.00, maintaining a Buy rating after the company reported mixed second-quarter results. The bank believes that despite a weakened guidance and investor concerns over Merck's group structure, there remains underlying value in the company, particularly in its Life Science business, with potential for stabilization in the third quarter due to improving performance and attractive valuation.